POST Online Media Lite Edition


Interleukin Genetics appoints two executives

Staff Writer |
Waltham, Mass., USA - August 5, 2016, Waltham, Mass., USA - Interleukin Genetics, a genetics-focused personalized health company, said that Stephan Toutain will join the company as chief commercial officer, a newly created role.

Article continues below

Mr. Toutain brings more than 25 years of commercial development, market access, and sales and marketing leadership with particular expertise in ultra-orphan drug and orphan oncology markets worldwide.

Mr. Toutain joins Interleukin Genetics following three years as a successful consultant to the biopharmaceutical industry addressing marketing strategy and access challenges.

Previously Mr. Toutain headed Global Commercial Development for Sarepta Therapeutics (Cambridge, MA), and served as General Manager for Alexion in Europe.

Prior to these roles, Mr. Toutain held various commercial, marketing and product management positions with Alexion Pharmaceuticals, Celgene Corporation, and Johnson & Johnson.

Mr. Toutain received a Master of Business Administration from University of North Carolina, and a Master of Engineering in Biotechnology from University of Nancy II in France.

Mary Hiter will become director of marketing, a created role.

Ms. Hiter will contribute nearly 20 years experience as a healthcare marketing executive, and has successfully launched multiple diagnostic, medical device and specialty pharmaceutical products.

Ms. Hiter joins Interleukin Genetics from Abbott Point of Care, where she served for eight years as Director of Marketing.

Prior to Abbott, Ms. Hiter held various marketing and product management roles with Cyberonics, Inc. (now Livanova), Watson Pharmaceuticals and Knoll Pharmaceuticals, Ltd.

She received a Bachelor of Science in Biology from Chatham College, Pittsburgh.

LATEST 5 MOVES FROM Massachusetts 

What to read next

Interleukin Genetics appoints Mark B. Carbeau as CEO
Response Genetics: David D. O'Toole new CFO
RiceBran Technologies appoints Robert Smith as CEO